The main aim of this thesis was to discover and design new ligands for difficult, under-explored and clinically relevant protein targets. A number of protein-protein interaction complexes (PPIs) are introduced as the target focus for the methods employed and developed herein. This thesis is separated into two sections to independently address both peptides and small molecules as screening agents. The project examines both approaches through comprehensive library design strategies and screening by NMR spectroscopic methods. ATAD2 is the first PPI investigated and was expressed and purified in good yield and was also isotopically labelled with Nitrogen-15 for enhanced sensitivity and orthogonal ligand and protein-observed NMR methods. A known pentapeptide was synthesised by solid-phase peptide synthesis (SPPS) using Fmoc chemistry for target validation and tool compound development. A one-bead one-compound (OBOC) tripeptide library was synthesised by SPPS in good yield and purity, determined using single-bead labelling techniques with a fluorescent dye (TMR) and HPLC analysis. This library contained 3072 unique tripeptides with 12 central non-natural, lysine derivatives flanked by 16 natural L amino acids. The library screening technique was based on using a fluorescently labelled protein and Confocal Nanoscanning to detect binding. However, fluorescent labelling of ATAD2 was unsuccessful due to difficult protein handling conditions, therefore this library was not screened. The advent of small molecule, high affinity inhibitors of this target protein generated by GSK shifted focus to a different PPI target, the ubiquitin conjugating enzyme, UbE2L3. A novel 'on-protein peptide building' approach was introduced with the aim of screening a library of fluorinated dipeptides and extending the most potent via the 'N' and 'C' terminus to increase the affinity. A proof-of-concept tetrapeptide to survivin was synthesised by SPPS by incorporation of a non-natural, fluorinated amino acid in the known tetrapeptide sequence. This fluorinated derivative showed target binding activity by 19F NMR spectroscopy. The tripeptide and dipeptide truncates were synthesised by SPPS and binding was still observable by 19F NMR. This method was extended to screening a library of synthesised fluorinated dipeptides by 19F NMR against UbE2L3. A single dipeptide was identified with low affinity and the dipeptide was extended C and N terminally by SPPS to increase affinity. However, there were no tripeptides identified for this protein using this method. The proof of concept tetrapeptide was a success, therefore further protein targets are required to conclusively assess the viability of the approach. Fragment based screening is then introduced as a second approach to novel ligand discovery. Coupled with cheminformatics analysis and in silico library design, we created an in-house fluorinated fragment library consisting of 109 fluorinated fragments using three parallel methods. Compounds were purchased and quality checked by LCMS, HPLC and 19F-NMR. These fragment libraries were screened in a 19F NMR assay against the UbE2L3 and NusE/NusB protein targets. In a primary mixture screen, two fragment hits were identified against the NusE/NusB PPI and there were no fragment hits identified against the UbE2L3 protein. The two fragments against NusE/NusB were validated using orthogonal ligand-binding NMR methods. A mini-series, consisting of six commercially available analogues, were purchased and two fragment analogues showed increased affinity and were active against E. coli in a bacterial inhibition assay. The dissociation constants of the six active compounds were determined by 15N-HSQC NMR titration experiments and shown to be in 100-500 μM range. The binding sites of each compound were also determined by 15N-HSQC chemical shift mapping. These fragment hits represent a novel chemical scaffold identified against the NusE/NusB PPI and demonstrate the potential druggability of this new, complex target. The use of fluorine as a sensor for binding detection is evaluated by incorporating into both peptides and fragments. Through the use of novel library design strategies, a campaign to discover novel ligands of difficult protein targets is presented.

Transcription factors control gene expression by binding to genomic DNA in a sequence-specific manner. Mutations in transcription factor binding sites are increasingly found to be associated with human disease, yet we currently lack robust methods to predict these sites. Here we developed a versatile maximum likelihood framework, named No Read Left Behind (NRLB), that fits a biophysical model of protein-DNA recognition to all in vitro selected DNA binding sites across the full affinity range. NRLB predicts human Max homodimer binding in near-perfect agreement with existing low-throughput measurements. The model captures the specificity of p53 tetrameric binding sites and discovers multiple binding modes in a single sample. Additionally, we confirm that newly-identified low-affinity enhancer binding sites are functional in vivo, and that their contribution to gene expression matches their predicted affinity. Our results establish a powerful paradigm for identifying protein binding sites and interpreting gene regulatory sequences in eukaryotic genomes.

Protein-Protein Interactions (PPIs) play a very important role in biological functions and therefore the inhibition of specific Protein-Protein Interactions has a huge therapeutic value. The most successful small molecular PPIs inhibitors do not fit with the prevalent `Rule of Five' drug profile. To overcome the disadvantages of small molecular PPIs inhibitors, peptide based PPIs inhibitors were developed. Herein we describe the development of a new class of peptidomimetics AA-peptides. The AApeptides were designed based on chiral PNA backbone. Substitution of nucleobases yields AApeptides that are resistant to proteolysis and capable of mimicking peptides. Two types of AApeptides were discussed in this dissertation "α-AApeptides" and "γ-AApeptides". The AApeptides were shown to disrupt p53/MDM2 protein-protein interaction and tomimic fMLF tripeptide to target G protein-coupled formyl peptide receptors (FPRs). Moreover, the lipidated α-AApeptides can mimic the structure and function of natural antimicrobial lipopeptides and show broad-spectrum activity against both Gram-positive and Gram-negative bacteria. Lastly I have designed and synthesized a serials of phosphopeptides to disrupt cancer related STAT3-STAT3 dimerization.

Thesis (Ph.D.)--McMaster University, 2005. / Supervisor: Dr. Christian Baron. Includes bibliographical references (leaves 94-101).

Thesis (Ph.D.) -- McMaster University, 2006. / Supervisor: David W. Andrews. Includes bibliographical references (leaves 110-117).

Thesis (Ph. D.)--University of Hong Kong, 2006. / Title proper from title frame. Also available in printed format.

Thesis (Ph. D.)--University of Hong Kong, 2007. / Title proper from title frame. Also available in printed format.

Thesis (Ph.D.)--Hong Kong University of Science and Technology, 2007. / Includes bibliographical references (leaves 161-195). Also available in electronic version.

Thesis (Ph. D.)--Ohio State University, 2006. / Full text release at OhioLINK's ETD Center delayed at author's request

Quenched Molecular Dynamics (QMD) used to explore molecular conformations was developed to operate in Insight II platform for two simulation engines: CHARMm and Discover. Two scripts and procedures were written for molecular minimization, dynamics, minimization of each of several hundred conformers, and cut off. Experience with Insight II/Discover versus Quanta/CHARMm, and between Insight II/CHARMm versus Quanta/CHARMm has taught that the forcefield is the key factor in QMD studies. Protein A has been used for the purification of commercial antibodies, but it is expensive. Seven peptidomimetics of protein A were designed based on the hot-spots located at the helix-loop-helix region of protein A, and synthesized via solid phase using the Fmoc approach. These peptidomimetics were characterized by MS and NMR. The conformations of four peptidomimetics were studied by NMR and CD in water/hexafluoroisopropanol (pH 4). The CD and NMR data show that addition of hexafluoroisopropanol stabilizes their a-helical conformations. The structures of these peptidomimetics in solution were generated with Quanta/CHARMm using NMR data as limits for the QMD technique. Protein G has also been used to purify antibodies, but it is expensive too. A number of protein G mimics were designed as trivalent molecules. An efficient preparation of trivalent molecules having a useful primary amine arm has been developed through solid phase synthesis. The cheap, commercially available poly(propylene imine) dendrimers were used as scaffolds which allow multimerization of functionalized compounds. A small library of trivalent compounds were synthesized using this approach. A portion of compounds in this library were tested by Amersham Biosciences. The seven amino acid modified DAB-Am-4 exhibits strong binding to the IgG/Fab, and is a potential ligand for IgG purification. The interactions between neurotrophins (ie NGF and NT-3) and their receptors are typical drug targets. Fourteen second-generation peptidomimetics showing NGF-like or NT3-like activities in a preliminary bioassay, were resynthesized and tested again. Preliminary and retested data were compared. To access a direct binding assay, five fluorescently labeled peptidomimetics 41a-e were synthesized for a fluorescence activated cell sorting (FACScan) assay. Six monomeric precursors 42 and 43 were prepared on large scales for the library of bivalent turn analogs